Azamian Bobak R. 4

What Happened
Bobak R. Azamian, President & CEO and Chairman of the Board of Tarsus Pharmaceuticals (TARS), received two equity awards on March 5, 2026: a grant of 96,723 derivative option shares (reported at $0.00) and 60,776 restricted stock units (RSUs) (reported at $0.00). These were awards/grants (code A on the Form 4) — no cash was paid by the insider. The filing does not list an immediate sale of shares.

Key Details

• Transaction date: March 5, 2026. Form 4 filed: March 9, 2026 (timely filed).
• Grants: 96,723 derivative option shares @ $0.00 (footnote F1) and 60,776 RSUs @ $0.00 (footnotes F2/F3).
• Vesting for the option shares (F1): 25% vests on March 5, 2027, then 1/48th of the option shares vest each month thereafter over 3 years, subject to continued service.
• RSU vesting (F2/F3): each RSU equals one share; RSUs vest in four equal annual installments on March 15 of 2027, 2028, 2029 and 2030, subject to continued service.
• Shares owned after the reported transactions: not specified in the provided filing details.
• No 10b5‑1 plan, tax withholding sale, or immediate cashless exercise/sale is indicated in the filing.

Context

• These entries are grants/awards (compensation/retention), not open‑market purchases or sales—often part of executive compensation packages.
• The option award is a derivative grant that will convert to exercisable options per the vesting schedule; RSUs convert to common shares upon vesting.
• Awards reported at $0.00 do not mean zero economic value — they reflect that the insider did not pay cash to acquire them; eventual value depends on future stock price and whether any exercise price applies (not specified in the provided excerpt).